4 days ago · Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term moderate to severe pain. includes Journavx side effects, uses, interactions, and more.

1 day ago · Journavx (Suzetrigine Tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.

JOURNAVX (suzetrigine) is an oral medication for the treatment of moderate-to-severe acute pain in adults. See Important Safety Information and Patient Information.

Jan 30, 2025 · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

6 days ago · The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

Jan 30, 2025 · -- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of...

6 days ago · The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Jan 30, 2025 · A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Jan 30, 2025 · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.

Jan 31, 2025 · Boston-based Vertex Pharmaceuticals developed Journavx, a non-addictive medication for people with moderate to severe acute pain. AP Photo/Bill Sikes A novel painkiller approved Thursday by the FDA promises to relieve post-surgical suffering while avoiding the addictive qualities of opioid medications. Boston-based Vertex Pharmaceuticals, which …